Arctic Therapeutics

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)	Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, psychiatric disorder	Active, not recruiting	Phase 2	2026-08-03		NCT07741526
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)	Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Amyloid Angiopathy, Familial, Cerebral Small Vessel Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemorrhage, Intracranial Hemorrhages, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, amyloidosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebral amyloid angiopathy, cerebral arterial disease, cerebrovascular disorder, cognitive disorder, dementia, hereditary amyloidosis, hereditary disease, inborn errors of metabolism, intracerebral hemorrhage, intracranial arterial disease, metabolic disease, nervous system disorder, proteostasis deficiencies, psychiatric disorder, vascular disorder	Active, not recruiting	Phase 2	2026-07-21		NCT07716865

Clinical trials